Hi Epichemist,
I really hope your estimates will prove being too cautious. If I peg your US sales estimates for Mar-Jun 2024 into the model, EYE would be a pretty far stretch off showing triple-digit growth numbers for the US in any of these months. Which I guess the market would consider as rather disapointing. And so would I.
I am surprised @TheAnalyst007 and @StealthInvest deem your estimate being „pretty reasonable“ and „a sensible ballpark“.
US$7-8 M for the US in 2H2024 (the key number to watch) should be needed to see the stock breaking the 28/30ct resistance. Without, I fear EYE would be left another six months without hard numbers that really underpin iTrack Advance‘ success for the broader and the professional investment community.
Good luck to all of us for next week.
POTENTIAL RE-RATE CATALYST EVENT: RESULTS, page-111
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.79M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $38.96K | 239.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4819 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 79620 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |